September 22, 2022
4 min watch
Save
VIDEO: Second-generation corneal endothelial cell therapy shows good results
Issue: October 25, 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
MILAN — At the ESCRS meeting, Shigeru Kinoshita, MD, PhD, joined virtually a symposium on emerging treatment options for corneal endothelial disease.
In this video perspective, he speaks about the results of his second-generation cell injection therapy supplemented by a ROCK inhibitor, a regenerative medicine technology that proved successful in studies for both Fuchs’ dystrophy and bullous keratopathy.
Published by:
Sources/Disclosures
Collapse
Source:
Kinoshita S. Endothelial cell stimulators (RHOK inhibitors and cell injection therapy). Presented at: European Society of Cataract and Refractive Surgeons meeting; Sept. 16-20, 2022; Milan.
Disclosures:
Kinoshita reports holding patents with Aurion Biotech for corneal endothelial cell therapy.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.